CRISIL Reaffirms Zydus Lifesciences Top-Tier Credit Ratings with Stable Outlook
Zydus Lifesciences Ltd 路 Others (Uncategorized) 路 11 Sept 2026, 8:05 pm
CRISIL Reaffirms Zydus Lifesciences Top-Tier Credit Ratings with Stable Outlook CRISIL Ratings reaffirmed Zydus Lifesciences Limited's long-term rating at CRISIL AAA/Stable for Rs. 4,724 crore bank facilities and Rs. 125 crore NCDs, alongside CRISIL A1+ for short-term facilities and Rs. 200 crore commercial paper on 10th Sep'26. Ratings reflect the company鈥檚 dominant domestic formulations standing, expanding international presence, and robust financial profile. Despite adjusted debt rising to Rs. 12,515 crore in FY26 due to acquisitions, net debt to Ebitda remained strong at 0.60x, with Rs. 7,465 crore in cash and equivalents ensuring superior liquidity.
Original exchange filing (PDF)
More announcements from Zydus Lifesciences Ltd
- Press Release 路 14 Nov 2026
- Completion of transaction 路 12 Nov 2026
- Transcript of the post results earnings call held on November 4, 2026. 路 07 Nov 2026
- Press Release 路 07 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Life Insurance Corporation of India 路 06 Nov 2026
- Investor Conference 路 06 Nov 2026
- Audio recording of the Company's Investor Call 路 05 Nov 2026
- Press Release 路 04 Nov 2026
